<DOC>
	<DOCNO>NCT00684255</DOCNO>
	<brief_summary>The purpose study determine reduce intensity ( RI ) ( non-myeloablative ) chemoimmunotherapy follow Allogeneic Stem Cell Transplantation AlloSCT ( match family donor match unrelated cord blood donor ) well tolerate .</brief_summary>
	<brief_title>Reduced Intensity Transplant Medically Refractory Systemic Lupus Erythematosus ( SLE ) Systemic Sclerosis ( SSc )</brief_title>
	<detailed_description>This test whether reduce intensity result high degree mix complete donor chimerism stabilization autoimmune disease select group patient medically refractory SLE SSc .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Diffuse Systemic Sclerosis variant per ACR criterion Medically refractory disease Adequate Organ Function Pulmonary function Renal function , Cardiac function define : SGOT ( AST ) SGPT ( ALT ) &lt; 5 x upper limit normal Diagnosis SLE Medically refractory disease Karnofsky/Lansky &lt; 60 %</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Reduced Intensity Transplant</keyword>
</DOC>